Market Overview

UPDATE: Jefferies Initiates Coverage on CVS Caremark on Position to Benefit from Multiple Catalysts

Share:
Related CVS
Benzinga's Top Upgrades, Downgrades For April 28, 2017
Express Scripts' Potential Breakup With Anthem, Explained
Swedbank Buys Pioneer Natural Resources Co, Synopsys, Adobe Systems, Sells CVS Health, ... (GuruFocus)

In a report published Tuesday, Jefferies analyst Mark Wiltamuth initiated coverage on CVS Caremark Corporation (NYSE: CVS) with a Buy rating and $71.00 price target.

In the report, Jefferies noted, “We recommend CVS Caremark as a core holding as we view it as the drug retailer best positioned to benefit from the Affordable Care Act, the aging of baby boomers and double-digit growth in specialty pharmacy. As the #1 US drugstore, #2 PBM, #2 in Medicare Part D insurance plans, and #2 in Specialty Pharmacy, the company's integrated PBM/retail model is best positioned to capture the coming shifts in the marketplace, in our view.”

CVS Caremark Corporation closed on Monday at $56.73.

Latest Ratings for CVS

DateFirmActionFromTo
Apr 2017Tigress FinancialInitiates Coverage OnBuy
Apr 2017Tigress FinancialInitiates Coverage OnBuy
Feb 2017BairdDowngradesOutperformNeutral

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: Jefferies Mark WiltamuthAnalyst Color Initiation Analyst Ratings

 

Related Articles (CVS)

View Comments and Join the Discussion!